istock-183060916
oonal / iStockphoto.com
26 September 2017Americas

Amgen secures $70m in biosimilar clash with Hospira

Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 August 2017   The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
Americas
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Big Pharma
21 December 2018   A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

More on this story

Americas
11 August 2017   The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
Americas
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Big Pharma
21 December 2018   A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

More on this story

Americas
11 August 2017   The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
Americas
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Big Pharma
21 December 2018   A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.